Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Synergy Bioscience is a U.S.-based CRDMO/CRO service provider in the pharmaceutical sector. The site positions the company as a “Contract Research, Development, Manufacturing, Testing, and Consulting Organization.” It is not a typical SaaS product; instead, it serves pharmaceutical, biologics, medical device, and combination product companies with drug development, laboratory testing, pilot manufacturing, and quality system compliance consulting.
Its core services cover the full drug development workflow: early-stage formulation, CMC strategy, analytical method development and validation, lyophilization, ADC/AOC development and pilot-scale work, microbiological testing, stability, dissolution, container closure integrity, residual solvents, elemental impurities, extractables/leachables, and more. Its testing services emphasize compliance with standards such as USP/NF, EP, BP, JP, ISO/IEC 17025, ISO 10993, USP 232/233, and ICH Q3D. The site also repeatedly mentions cGMP, FDA warning letter remediation, supplier audits, cleaning validation, and quality system consulting, indicating that its main value proposition lies in regulatory experience and laboratory capabilities.
The website does not publish packages, individual testing prices, or subscription plans. It only provides a “Get a Quote” inquiry option, so pricing is project-based and customized. The founder’s introduction emphasizes reducing costs through in-house laboratories and professional staff, especially with the goal of serving small and mid-sized pharmaceutical companies. However, specific fees, delivery timelines, and SLAs are not disclosed.
From an enterprise software perspective, the site does not mention a customer portal, cloud platform, self-hosting, APIs, third-party integrations, account permissions, audit logs, or developer documentation. As a result, it cannot be evaluated using the usual SaaS procurement logic. It is better assessed as a professional outsourcing service, with focus on laboratory capabilities, compliance credentials, and project management ability.
Its strengths include a long service chain, a broad range of testing items, a clear compliance narrative, and case-related references such as FDA remediation, cleaning validation, and facility transfer. Its weaknesses are average commercial transparency and the lack of information on pricing, payment, data security certifications, and online collaboration capabilities. It is suitable for pharmaceutical companies, biotech teams, and medical device teams that need formulation development, analytical validation, cGMP remediation, or quality system development.
The site does not specify access conditions from China, nor does it disclose payment methods or cross-border service arrangements. Before procurement, buyers should confirm sample cross-border logistics, contracts, payment, and time zone communication. Local China or Asia-Pacific alternatives may include WuXi AppTec and Pharmaron; internationally, it can be compared with laboratory and CRO/CDMO providers such as Charles River, Eurofins, SGS, and Intertek.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on synergybioscience.com official site.
synergybioscience.com is an United States Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach synergybioscience.com directly.